Comparison of18f-fet pet and perfusion-weighted mr imaging: A pet/mr imaging hybrid study in patients with brain tumors

Journal of Nuclear Medicine

Volumn 55, Issue 4, 2014, Pages 540-545

  Filss, Christian P ^a   Galldiks, Norbert ^a,b   Stoffels, Gabriele ^a   Sabel, Michael ^c   Wittsack, Hans J ^c   Turowski, Bernd ^c   Antoch, Gerald ^c   Zhang, Ke ^a   Fink, Gereon R ^a,b   Coenen, Heinz H ^a,d   Shah, Nadim J ^a,d,e   Herzog, Hans ^a,d   Langen, Karl Josef ^a,d,e  

^a FORSCHUNGSZENTRUM JÜLICH   (Germany)

^b UNIVERSITY OF COLOGNE   (Germany)

^c HEINRICH HEINE UNIVERSITY   (Germany)

^d Julich Aachen Research Alliance JARA   (Germany)

^e UNIVERSITY HOSPITAL RWTH AACHEN   (Germany)

Author keywords

Glioma; Histogram; PET MR imaging; PWI; RCBV

Indexed keywords

FLUORODEOXYGLUCOSE F 18; DIAGNOSTIC AGENT; RADIOPHARMACEUTICAL AGENT;

ADULT; AGED; ARTICLE; BRAIN MAPPING; BRAIN TUMOR; CANCER LOCALIZATION; CONTRAST ENHANCEMENT; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC IMAGING; DIAGNOSTIC TEST ACCURACY STUDY; FEMALE; GLIOMA; HISTOGRAM; HUMAN; IMAGE ANALYSIS; MAJOR CLINICAL STUDY; MALE; MENINGIOMA; NEUROIMAGING; OUTCOME ASSESSMENT; PERFUSION WEIGHTED IMAGING; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; SENSITIVITY ANALYSIS; TUMOR VOLUME; CEREBROSPINAL FLUID; COMPARATIVE STUDY; IMAGE PROCESSING; METHODOLOGY; MIDDLE AGED; NUCLEAR MAGNETIC RESONANCE IMAGING; O-(2-18F-FLUOROETHYL)-L-TYROSINE; PATHOLOGY; PET/MR IMAGING; PWI; RCBV; SCINTIGRAPHY; SCINTISCANNING; STATISTICAL ANALYSIS; YOUNG ADULT;

GLIOMA; HISTOGRAM; O-(2-18F-FLUOROETHYL)-L-TYROSINE; PET/MR IMAGING; PWI; RCBV;

ADULT; AGED; BRAIN NEOPLASMS; DATA INTERPRETATION, STATISTICAL; FEMALE; FLUORODEOXYGLUCOSE F18; GLIOMA; HUMANS; IMAGE PROCESSING, COMPUTER-ASSISTED; MAGNETIC RESONANCE IMAGING; MALE; MENINGIOMA; MIDDLE AGED; PERFUSION IMAGING; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS; YOUNG ADULT;

EID: 84901358325     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: 10.2967/jnumed.113.129007     Document Type: Article

References (34)

1. Cha S. Neuroimaging in neuro-oncology. Neurotherapeutics. 2009;6:465-477.
2. Tsien C, Galban CJ, Chenevert TL, et al. Parametric response map as an imaging biomarker to distinguish progression from pseudoprogression in high-grade glioma. J Clin Oncol. 2010;28:2293-2299.
3. Lacerda S, Law M. Magnetic resonance perfusion and permeability imaging in brain tumors. Neuroimaging Clin N Am. 2009;19:527-557.
4. Zikou AK, Alexiou GA, Kosta P, et al. Diffusion tensor and dynamic susceptibility contrast MRI in glioblastoma. Clin Neurol Neurosurg. 2012;114:607-612.
5. Barajas RF Jr, Phillips JJ, Parvataneni R, et al. Regional variation in histopathologic features of tumor specimens from treatment-naive glioblastoma correlates with anatomic and physiologic MR imaging. Neuro-oncol. 2012;14:942-954.
6. Maia AC Jr, Malheiros SM, da Rocha AJ, et al. MR cerebral blood volume maps correlated with vascular endothelial growth factor expression and tumor grade in nonenhancing gliomas. Am J Neuroradiol. 2005;26:777-783.
7. Sadeghi N, D'Haene N, Decaestecker C, et al. Apparent diffusion coefficient and cerebral blood volume in brain gliomas: relation to tumor cell density and tumor microvessel density based on stereotactic biopsies. Am J Neuroradiol. 2008;29:476-482.
8. Liu X, TianW, Kolar B, et al.MR diffusion tensor and perfusion-weighted imaging in preoperative grading of supratentorial nonenhancing gliomas. Neuro-oncol. 2011;13:447-455.
9. Galbán CJ, Chenevert TL, Meyer CR, et al. Prospective analysis of parametric response map-derived MRI biomarkers: identification of early and distinct glioma response patterns not predicted by standard radiographic assessment. Clin Cancer Res. 2011;17:4751-4760.
10. Law M, Young RJ, Babb JS, et al. Gliomas: predicting time to progression or survival with cerebral blood volume measurements at dynamic susceptibilityweighted contrast-enhanced perfusion MR imaging. Radiology. 2008;247:490-498.
11. Dandois V, Rommel D, Renard L, Jamart J, Cosnard G. Substitution of 11Cmethionine PET by perfusion MRI during the follow-up of treated high-grade gliomas: preliminary results in clinical practice. J Neuroradiol. 2010;37:89-97.
12. Herholz K, Langen KJ, Schiepers C, Mountz JM. Brain tumors. Semin Nucl Med. 2012;42:356-370.
13. Langen KJ, Hamacher K, Weckesser M, et al. O-(2-[18F]fluoroethyl)-L- tyrosine: uptake mechanisms and clinical applications. Nucl Med Biol. 2006;33:287-294.
14. Floeth FW, Pauleit D, Sabel M, et al. Prognostic value of O-(2-18F-fluoroethyl)-L-tyrosine PET and MRI in low-grade glioma. J Nucl Med. 2007;48: 519-527.
15. Galldiks N, Langen K, Holy R, et al. Assessment of treatment response in patients with glioblastoma using [18F]fluoroethyl-L-tyrosine PET in comparison to MRI. J Nucl Med. 2012;53:1048-1057.
16. Pauleit D, Floeth F, Hamacher K, et al. O-(2-[18F]fluoroethyl)-L-tyrosine PET combined with MRI improves the diagnostic assessment of cerebral gliomas. Brain. 2005;128:678-687.
17. Pauleit D, Stoffels G, Bachofner A, et al. Comparison of 18F-FET and 18F-FDG PET in brain tumors. Nucl Med Biol. 2009;36:779-787.
18. Pöpperl G, Götz C, Rachinger W, Gildehaus FJ, Tonn JC, Tatsch K. Value of O-(2-[18F]fluoroethyl)-L-tyrosine PET for the diagnosis of recurrent glioma. Eur J Nucl Med Mol Imaging. 2004;31:1464-1470.
19. Sadeghi N, Salmon I, Decaestecker C, et al. Stereotactic comparison among cerebral blood volume, methionine uptake, and histopathology in brain glioma. Am J Neuroradiol. 2007;28:455-461.
20. Sadeghi N, Salmon I, Tang BN, et al. Correlation between dynamic susceptibility contrast perfusion MRI and methionine metabolism in brain gliomas: preliminary results. J Magn Reson Imaging. 2006;24:989-994.
21. Kim YH, Oh SW, Lim YJ, et al. Differentiating radiation necrosis from tumor recurrence in high-grade gliomas: assessing the efficacy of 18F-FDG PET, 11C-methionine PET and perfusion MRI. Clin Neurol Neurosurg. 2010;112: 758-765.
22. Zimny A, Sasiadek M. Contribution of perfusion-weighted magnetic resonance imaging in the differentiation of meningiomas and other extra-axial tumors: case reports and literature review. J Neurooncol. 2011;103:777-783.
23. Herzog H, Langen KJ, Weirich C, et al. High resolution BrainPET combined with simultaneous MRI. Nuklearmedizin. 2011;50:74-82.
24. Wittsack HJ, Ritzl A, Modder U. User friendly analysis of MR investigations of the cerebral perfusion: Windows(R)-based image processing [in German]. Rofo. 2002;174:742-746.
25. Emblem KE, Nedregaard B, Nome T, et al. Glioma grading by using histogram analysis of blood volume heterogeneity from MR-derived cerebral blood volume maps. Radiology. 2008;247:808-817.
26. Friedman SN, Bambrough PJ, Kotsarini C, Khandanpour N, Hoggard N. Semiautomated and automated glioma grading using dynamic susceptibility-weighted contrast-enhanced perfusion MRI relative cerebral blood volume measurements. Br J Radiol. 2012;85:e1204-e1211.
27. Emblem KE, Scheie D, Due-Tonnessen P, et al. Histogram analysis of MR imagingderived cerebral blood volume maps: combined glioma grading and identification of low-grade oligodendroglial subtypes. Am J Neuroradiol. 2008;29:1664-1670.
28. Ulmer S, Liess C, Kesari S, Otto N, Straube T, Jansen O. Use of dynamic susceptibility-contrast MRI (DSC-MRI) to assess perfusion changes in the ipsilateral brain parenchyma from glioblastoma. J Neurooncol. 2009;91:213-220.
29. Hu LS, Baxter LC, Pinnaduwage DS, et al. Optimized preload leakage-correction methods to improve the diagnostic accuracy of dynamic susceptibilityweighted contrast-enhanced perfusion MR imaging in posttreatment gliomas. Am J Neuroradiol. 2010;31:40-48.
30. Wetzel SG, Cha S, Johnson G, et al. Relative cerebral blood volume measurements in intracranial mass lesions: interobserver and intraobserver reproducibility study. Radiology. 2002;224:797-803.
31. Paulson ES, Schmainda KM. Comparison of dynamic susceptibility-weighted contrast-enhanced MR methods: recommendations for measuring relative cerebral blood volume in brain tumors. Radiology. 2008;249:601-613.
32. Kracht LW, Friese M, Herholz K, et al. Methyl-[11C]-l-methionine uptake as measured by positron emission tomography correlates to microvessel density in patients with glioma. Eur J Nucl Med Mol Imaging. 2003;30:868-873.
33. Di Ieva A, Grizzi F, Tschabitscher M, et al. Correlation of microvascular fractal dimension with positron emission tomography [11C]-methionine uptake in glioblastoma multiforme: preliminary findings. Microvasc Res. 2010;80:267-273.
34. Wyss MT, Hofer S, Hefti M, et al. Spatial heterogeneity of low-grade gliomas at the capillary level: a PET study on tumor blood flow and amino acid uptake. J Nucl Med. 2007;48:1047-1052.